- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04471844
Estudo Pivotal, Randomizado, Aberto de Optune® (Campos de Tratamento de Tumores) Concomitante com RT e TMZ para o Tratamento de GBM Recentemente Diagnosticado (EF-32)
EF-32: Estudo Pivotal, Randomizado, Aberto de Optune® (Campos de Tratamento de Tumores, 200kHz) Concomitante com Radioterapia e Temozolomida para o Tratamento de Glioblastoma Recentemente Diagnosticado
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
Visão geral do estudo
Descrição detalhada
Optune® is a medical device that has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States. Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.
The current standard of care for GBM includes the addition of Optune® to maintenance temozolomide (TMZ), following the completion of radiation therapy (RT).
The purpose of the current study is to test if the earlier introduction of Optune®, at the time of radiation therapy (which is given together with temozolomide), improves clinical outcomes compared to the standard of care.
The study will randomize 950 subjects equally to one of two treatment arms:
- Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment.
- Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune®.
All patients are to receive standard RT and TMZ treatment followed by maintenance TMZ chemotherapy and Optune® according to the current standard of care regimen.
Optune® will continue until second disease progression per 2010 RANO Criteria unless any of the treatment discontinuation conditions described under criteria for patient withdrawal or termination are met.
After surgery or biopsy, subjects that would like to participate will be required to submit samples of their tumor to a lab for testing. The results of this test will be used for randomization into the trial.
If the subject is assigned to the treatment group that will start Optune® therapy during radiation therapy, Optune® therapy will begin within 10 days of enrolling in the study and no later than the first day of RT and TMZ treatment.
After the initial visit, subjects will continue treatment at home, while pursuing normal daily routines. Subjects are required to use the device for at least 18 hours a day. Short breaks in treatment for personal hygiene and other personal needs is allowed. Total usage time will be recorded and provided to the site and sponsor.
Subjects will be required to return to the clinic per the study protocol.
After the second disease progression, subjects will return to the clinic for one final visit approximately 30 days after the last treatment with Optune® or after second disease progression, the latter of the two per protocol.
After completing active participation in the study, subjects will be contacted once per month to answer basic questions about their health status.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Essen, Alemanha, 45147
- University Hospital Essen
-
Freiburg im Breisgau, Alemanha, 79106
- University Medical Center Freiburg
-
Leipzig, Alemanha, 04103
- University Hospital Leipzig
-
Munich, Alemanha, 81675
- Rechts der Isar Hospital
-
Tübingen, Alemanha, 72076
- University Hospital Tübingen
-
-
-
-
-
Liège, Bélgica, B35, 4000
- University Hospital Liege - Sart Tilman
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- BC Cancer - Vancouver
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canadá, B1P 1P3
- Nova Scotia Health Authority
-
-
Ontario
-
Ottawa, Ontario, Canadá
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Canadá
- Princess Margaret Cancer Centre
-
Toronto, Ontario, Canadá
- Sunnybrook Research Institute - Odette Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X1R9
- CHUM Centre de Recherche
-
Sherbrooke, Quebec, Canadá
- Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35243
- Grandview Cancer Center
-
-
Arizona
-
Gilbert, Arizona, Estados Unidos, 85234
- Banner MD Anderson Cancer Center
-
Phoenix, Arizona, Estados Unidos, 85054
- Mayo Clinic- Arizona
-
Tucson, Arizona, Estados Unidos, 85719
- University of Arizona Cancer Center
-
-
Arkansas
-
Fayetteville, Arkansas, Estados Unidos, 72762
- Highlands Oncology Group
-
-
California
-
Burbank, California, Estados Unidos, 91505
- Providence St. Joseph Medical Center and The Roy and Patricia Disney Family Cancer Center
-
Duarte, California, Estados Unidos, 91010
- City of Hope National Medical Center
-
Fullerton, California, Estados Unidos, 92835
- TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center
-
La Jolla, California, Estados Unidos, 92093
- University of California at San Diego - Moores Cancer Center
-
Los Angeles, California, Estados Unidos, 90048
- Cedars - Sinai Medical Center
-
Los Angeles, California, Estados Unidos, 90033
- Norris Comprehensive Cancer Center at USC
-
Newport Beach, California, Estados Unidos, 92663
- Hoag Memorial Hospital - Hoag Cancer Center
-
Orange, California, Estados Unidos, 92868
- St. Joseph Hospital of Orange
-
Orange, California, Estados Unidos, 92868
- University of California - Irvine/UCI Medical Center
-
Palo Alto, California, Estados Unidos, 94303
- Stanford University Cancer Institute
-
San Diego, California, Estados Unidos, 92123
- Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology
-
San Francisco, California, Estados Unidos, 94143
- University of California San Francisco Medical Center
-
Santa Monica, California, Estados Unidos, 90404
- John Wayne Cancer Institute at St. John's Health Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Cancer Center Anschutz
-
Englewood, Colorado, Estados Unidos, 80113
- HCA Research Institute - Blue Sky Neurology - Denver
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06106
- Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33486
- Lynn Cancer Institute, Marcus Neuroscience Institute
-
Jacksonville, Florida, Estados Unidos, 32224
- Mayo Clinic
-
Jacksonville, Florida, Estados Unidos, 32207
- Baptist Health - Jacksonville
-
Orlando, Florida, Estados Unidos, 32804
- AdventHealth
-
Orlando, Florida, Estados Unidos, 32806
- Orlando Health UF Health Cancer Center
-
Tampa, Florida, Estados Unidos, 33612
- H. Lee Moffitt Cancer Center and Research Institute, Inc
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Northside Hospital, Inc.
-
Atlanta, Georgia, Estados Unidos, 30309
- Piedmont Healthcare Brain Tumor Center
-
Atlanta, Georgia, Estados Unidos, 30322
- The Emory Clinic - Emory Healthcare - Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Rush University Medical Center
-
Chicago, Illinois, Estados Unidos, 60617
- University of Chicago
-
-
Indiana
-
Fort Wayne, Indiana, Estados Unidos, 46845
- Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates
-
-
Kansas
-
Topeka, Kansas, Estados Unidos, 66606
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40241
- Norton Cancer Institute
-
Louisville, Kentucky, Estados Unidos, 40202
- University of Louisville - James Graham Brown Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70810
- Mary Bird Cancer Center Neuromedical Center
-
New Orleans, Louisiana, Estados Unidos, 70072
- LSU Health Sciences Center, New Orleans
-
New Orleans, Louisiana, Estados Unidos, 70121-2429
- Ochsner Health System
-
-
Maine
-
South Portland, Maine, Estados Unidos, 04106
- Maine Medical Partners Neurology - Neurosurgery & Spine Associates
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- John Hopkins School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02111
- Tufts Medical Center
-
Worcester, Massachusetts, Estados Unidos, 01655
- University of Massachusetts Chan Medical School
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Abbott Northwestern Hospital - Givens Brain Tumor Center
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65212
- University of Missouri - Ellis Fischel Cancer Center
-
Kansas City, Missouri, Estados Unidos, 64132
- Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Edison, New Jersey, Estados Unidos, 08820
- JFK Neuroscience Institute, HMH JFK University Medical Center
-
Hackensack, New Jersey, Estados Unidos, 07601
- Hackensack University Medical Center - John Theurer Cancer Center
-
Neptune City, New Jersey, Estados Unidos, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Lake Success, New York, Estados Unidos, 11042
- Northwell Health System Brain Tumor Center
-
New York, New York, Estados Unidos, 10029
- Mount Sinai - Icahn School of Medicine
-
New York, New York, Estados Unidos, 10016
- NYU Langone - Laura & Issac Perimutter Cancer Center
-
New York, New York, Estados Unidos, 10032
- New York Presbyterian - Columbia University
-
Rochester, New York, Estados Unidos, 14642
- University of Rochester Medical Center
-
Syracuse, New York, Estados Unidos, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Estados Unidos, 28204
- Novant Health Cancer Institute Radiation Oncology
-
Greenville, North Carolina, Estados Unidos, 27834
- Vidant Medical Center
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Wake Forest Baptist Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Forsyth Medical Center-Novant Health
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- University of Cincinnati Cancer Institute
-
Columbus, Ohio, Estados Unidos, 43210
- The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Neuroscience Center, Philadelphia - University of Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212
- Allegheny Health Network Cancer Institute
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- MUSC Radiation Oncology Brain & Spine Tumor Program
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37404
- SCRI - Tennessee Oncology
-
Germantown, Tennessee, Estados Unidos, 38138
- West Cancer Center - Germantown
-
Nashville, Tennessee, Estados Unidos, 37203
- SCRI - Tennessee Oncology
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- Texas Oncology Midtown - Austin Brain Tumor Center
-
Dallas, Texas, Estados Unidos, 75246
- Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center
-
Fort Worth, Texas, Estados Unidos, 76104
- John Peter Smith Health Network - JPS Cancer Center
-
Houston, Texas, Estados Unidos, 77030
- Houston Methodist Hospital
-
Houston, Texas, Estados Unidos, 77030
- UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences
-
Temple, Texas, Estados Unidos, 76508
- Baylor Scott & White Medical Center
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05401
- The University of Vermont Medical Center - University of Vermont Cancer Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Health Services
-
Seattle, Washington, Estados Unidos, 98109
- UW Medical Center - Alvord Brain Tumor Center
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
- West Virginia University Cancer Institute
-
-
-
-
-
Angers, França, 49055
- Institut de cancérologie de l'Ouest
-
Bron, França, 69677
- Pierre Wertheimer Hospital
-
Marseille, França, 13305
- Hôpital la Timone
-
Nice, França, 06000
- University Hospital Nice
-
Paris, França, 75013
- Pitié-Salpêtrière University Hospital
-
Saint-Herblain, França, 44800
- Institut de cancérologie de l'Ouest
-
Toulouse, França, 31059
- University Institute Cancer Toulouse Oncopole
-
Villejuif, França, 94805
- Gustave Roussy Institute
-
-
-
-
-
Jerusalem, Israel, 9112001
- Hadassah Medical Center - Ein Kerem
-
-
Haifa District
-
Haifa, Haifa District, Israel, 3109601
- Rambam Medical Center
-
-
Petah Tikva
-
Petah Tikva, Petah Tikva, Israel, 49100
- Rabin Medical Center
-
-
Ramat Gan
-
Ramat Gan, Ramat Gan, Israel, 52621
- Sheba Medical Center
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
Hokkaido
-
Sapporo, Hokkaido, Japão, 060-8648
- Hokkaido University Hospital
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japão, 920-8641
- Kanazawa University Hospital
-
-
Saitama
-
Hidaka-shi, Saitama, Japão, 350-1298
- Saitama Medical University International Medical Center
-
-
Tokyo-To
-
Mitaka-shi, Tokyo-To, Japão, 181-8611
- Kyorin University Hospital
-
Shinjuku-ku, Tokyo-To, Japão, 162-8666
- Tokyo Women's Medical University Hospital
-
-
-
-
-
Liverpool, Reino Unido, L7 8YA
- Clatterbridge Cancer Centre
-
London, Reino Unido, SE1 9RT
- Guy's Hospital
-
London, Reino Unido, W6 8RF
- Charing Cross Hospital
-
Nottingham, Reino Unido, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Preston, Reino Unido, PR29HT
- Royal Preston Hospital
-
-
-
-
-
Lausanne, Suíça, CH-1011
- Lausanne University Hospital
-
Zurich, Suíça, 8091
- University Hospital Zurich
-
-
-
-
Brno
-
Brno, Brno, Tcheca, 656 53
- Masaryk Memorial Cancer Institute
-
-
Pilsen
-
Pilsen, Pilsen, Tcheca, 305 99
- University Hospital Plzeň
-
-
Prague
-
Prague, Prague, Tcheca, 150 30
- Na Homolce Hospital
-
-
-
-
Innsbruck
-
Innsbruck, Innsbruck, Áustria, 6020
- Innsbruck University Hospital
-
-
Linz
-
Linz, Linz, Áustria, 4020
- Kepler University Hospital
-
-
State of Salzburg
-
Salzburg, State of Salzburg, Áustria, 5020
- University Hospital Salzburg
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
*Age Limits - 18 years or older outside of the US, 22 years or older within the US.
Inclusion Criteria:
- Histologically confirmed diagnosis of GBM according to WHO 2016 classification criteria.
- Age ≥ 22 years in US and Age ≥ 18 years in Ex-US
- Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
- Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
- Karnofsky performance status ≥ 70
- Life expectancy ≥ least 3 months
- Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynecologist as needed.
- All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
- Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable.
- Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery
- Women of childbearing potential must have a negative β-HCG pregnancy test documented within 14 days prior to randomization
- Is able to have MRI with contrast of the brain
Exclusion Criteria:
-
Progressive disease (per investigator's assessment)
-
Infratentorial or leptomeningeal disease
-
Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study
-
Pregnancy or breast-feeding.
-
Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator:
- Thrombocytopenia (platelet count < 100 x 103/μL)
- Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
- CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
- Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
- Total bilirubin > 1.5 x upper limit of normal
- Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)
- History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
-
Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.
-
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
-
History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.
-
Additional malignancies that are progressing or required active treatment in the last two years.
-
Admitted to an institution by administrative or court order.
-
Known allergies to medical adhesives or hydrogel
-
A skull defect (such as, missing bone with no replacement)
-
Prior radiation treatment to the brain for the treatment of GBM
-
Any serious surgical/post-operative condition that may put the participant at risk according to the investigator.
-
Standard TTFields exclusion criteria include
- Active implanted medical devices
- Bullet fragments
- Skull defects
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Optune® + RT + TMZ for 6 weeks
Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
|
Comparador Ativo: RT +TMZ for 6 weeks
RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Survival (OS)
Prazo: 5 years
|
Survival will be measured from the time of randomization until date patient is alive. |
5 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression Free Survival (PFS)
Prazo: 5 years
|
PFS will be measured from the date of randomization to the date of progression based on the 2010 RANO Criteria. |
5 years
|
|
1- and 2-year survival rates
Prazo: 5 years
|
The analyses will be performed based on estimated proportions of patients who are on study at 12 and 24 months in both arms of the study. |
5 years
|
|
Overall Radiological response (ORR)
Prazo: 5 years
|
The analyses will be performed based on the 2010 RANO criteria, and comparison between the rates of response. |
5 years
|
|
Next progression-free survival (PFS2)
Prazo: 5 years
|
PFS2 will be measured from the time of randomization to second tumor progression. |
5 years
|
|
Progression-free survival at 6 (PFS6) and 12 months (PFS12)
Prazo: 5 years
|
The analyses will be estimated proportions of patients who are progression-free at 6 and 12 months in both arms of the study. |
5 years
|
|
Severity and frequency of adverse events
Prazo: 5 years
|
The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments. |
5 years
|
|
Quality of Life EORTC Questionnaire
Prazo: 5 years
|
The analyses will be assessed using the EORTC QLQ C-30 questionnaire with BN-20 (brain symptom) supplement. |
5 years
|
|
The NANO scale
Prazo: 5 years
|
The Neurological assessment in Neuro-Oncology will be assessed using the NANO scale questionnaire and per the 2010 RANO criteria. |
5 years
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Miller R, Niazi M, Russial O, Poiset S, Shi W. Tumor treating fields with radiation for glioblastoma: a narrative review. Chin Clin Oncol. 2022 Oct;11(5):40. doi: 10.21037/cco-22-90.
- Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, Glass J, Alnahhas I, Andrews D, Judy K, Evans J, Farrell C, Werner-Wasik M, Chervoneva I, Ly M, Palmer J, Liu H, Shi W. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Front Oncol. 2022 Apr 29;12:896246. doi: 10.3389/fonc.2022.896246. eCollection 2022.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TRIDENT EF-32
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .